The Asia Pacific hemoglobinopathies market was valued at USD 1.91 Billion in 2025 and is expected to grow at a CAGR of 10.30%, reaching USD 5.09 Billion by 2035. The market growth is driven by increasing incidence of thalassemia and sickle cell anemia across the region. Supportive government policies, awareness programs, and funding for disease management are further fueling the market growth.
Base Year
Historical Period
Forecast Period
Thalassemia is considered the most common hereditary hemoglobinopathy affecting 4.4 of every 10,000 live births . It is reported to be highly prevalent in Southeast Asia and southern China. The rising burden of these genetic blood disorders is expected to drive market demand.
One of the major Asia Pacific hemoglobinopathies market trends is the growing emphasis on the development of advanced hemoglobinopathies therapies that can eliminate the need for blood transfusions. In January 2024, CorrectSequence Therapeutics in collaboration with Guangxi Medical University, announced that they had clinically cured a thalassemia patient using a genetic base-editing technology called CS-101.
The National Sickle Cell Anaemia Elimination Mission was launched by the Indian government in July 2023 to facilitate screening, prevention, and management of sickle cell anemia. Such initiatives are likely to enhance the detection and management of hemoglobinopathies, which is anticipated to boost the market share.
Compound Annual Growth Rate
10.3%
Value in USD Billion
2026-2035
*this image is indicative*
Hemoglobinopathies are a group of inherited blood disorders that cause abnormalities in the structure or production of hemoglobin. These disorders can result in severe health issues such as anemia, tissue damage, and organ dysfunction. Common hemoglobinopathies include sickle cell disease and thalassemia. The rising advancements in drug development and gene therapy coupled with the increased availability and adoption of advanced treatments are significantly contributing to the Asia Pacific hemoglobinopathies market growth.
Recent data suggests that around 300,000 to 500,000 children are born with severe hemoglobinopathies, out of which nearly 80% of the cases occur in developing countries. Thalassemia is considered the most common hereditary hemoglobinopathy, affecting 4.4 of every 10,000 live births . It is reported to be prevalent in Southeast Asia and southern China. The rising burden of these genetic blood disorders necessitates the need for advanced diagnostics and treatments, which are likely to augment the Asia Pacific hemoglobinopathies market demand in the forecast period.
One of the major market trends is the growing emphasis on the development of innovative hemoglobinopathies therapies. In January 2024, a China-based gene-editing pharmaceutical company CorrectSequence Therapeutics in collaboration with Guangxi Medical University, announced that they had clinically cured an adolescent patient with transfusion-dependent beta-thalassemia using a genetic base-editing one-time treatment called CS-101. The rising introduction of such advanced therapies in clinical settings that can eliminate the need for blood transfusions in such conditions is poised to boost the Asia Pacific hemoglobinopathies market share.
The market is also influenced by increased government initiatives such as screening programs and awareness campaigns to educate the public regarding the management and associated risks with the disorders. For instance, in July 2023, the Indian government initiated the National Sickle Cell Anaemia Elimination Mission, intended to facilitate screening, prevention, and management of sickle cell anemia in all tribal and other highly prevalent regions of India. Under the program, over 1 crore (10 million) people were screened for sickle cell anemia within 1 year. Such initiatives are likely to enhance the detection and management of hemoglobinopathies, which is anticipated to propel the market growth in the coming years.
Asia Pacific Hemoglobinopathies Market Report and Forecast 2026-2035 offers a detailed analysis of the market based on the following segments:
Breakup by Type
Breakup by Treatment
Breakup by Test Type
Breakup by End User
Breakup by Region
The key features of the market report include patent analysis, grants analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Upto 15% Off
USD
$4299 $3869
$2699 $2429
$5799 $4949
$6999 $5949
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
The Asia Pacific hemoglobinopathies market is expected to be driven by the rising demand for the global market, which is anticipated to grow at a CAGR of 10.30% during the forecast period of 2026-2035 and is likely to reach a market value of USD 5.09 Billion by 2035.
The rising prevalence of thalassemia and sickle cell anemia, along with increased awareness on managing the condition is fuelling the demand for the market.
One of the significant trends in the market is the growing emphasis on the development of advanced hemoglobinopathies therapies. In January 2024, CorrectSequence Therapeutics in collaboration with Guangxi Medical University had clinically cured an adolescent patient with thalassemia using a genetic base-editing technology.
Based on the type, the market is segmented into thalassemia, sickle cell disease, and other Hb variants diseases.
Treatments available in the market include stem-cell transplantation, blood transfusions, analgesics, antibiotics, ace inhibitors, hydroxyurea, and monoclonal antibody medication, among others.
By test type, the market is divided into routine red blood Cell (RBC) count, genetic testing, hemoglobin by high performance liquid chromatograph (Hb HPLC), hemoglobin isoelectric focusing (Hb IEF), hemoglobin electrophoresis (Hb ELP), and hemoglobin solubility test.
End users of the market are hospitals, clinics, and diagnostics laboratories, among others.
The market segmentation by countries includes China, Japan, India, ASEAN, and Australia, among others.
The key players in the market are Bio-Rad Laboratories, Inc., Bristol-Myers Squibb Company, Novartis AG, Pfizer Limited, Merck KGaA, Alnylam Pharmaceuticals, Inc., Sanofi, Neusoft Corporation, Emmaus UK, and Biogen.
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Type |
|
| Breakup by Treatment |
|
| Breakup by Test Type |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Single User License
One User
USD 4,299
USD 3,869
tax inclusive*
Datasheet
One User
USD 2,699
USD 2,429
tax inclusive*
Five User License
Five User
USD 5,799
USD 4,949
tax inclusive*
Corporate License
Unlimited Users
USD 6,999
USD 5,949
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share